Search Results - Odile Beyne-Rauzy

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes? by Olivier Kosmider, Marie Passet, Valeria Santini, Uwe Platzbecker, Valérie Andrieu, Gina Zini, Odile Beyne-Rauzy, Agnès Guerci, Erico Masala, Enrico Balleari, Ekaterina Bulycheva, François Dreyfus, Pierre Fenaux, Michaela Fontenay, Sophie Park

    Published in Haematologica (2016-07-01)
    Get full text
    Article


  2. 2

    TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia by Olivier Kosmider, Véronique Gelsi-Boyer, Marion Ciudad, Cindy Racoeur, Valérie Jooste, Norbert Vey, Bruno Quesnel, Pierre Fenaux, Jean-Noël Bastie, Odile Beyne-Rauzy, Aspasia Stamatoulas, François Dreyfus, Norbert Ifrah, Stéphane de Botton, William Vainchenker, Oliver A. Bernard, Daniel Birnbaum, Michaëla Fontenay, Eric Solary

    Published in Haematologica (2009-12-01)
    Get full text
    Article


  3. 3

    S162: LOSS OF HEMATOPOIETIC PROGENITORS HETEROGENEITY IS AN ADVERSE PROGNOSTIC FACTOR IN MYELODYSPLASTIC SYNDROMES by Charles Dussiau, Thibault Comont, Camille Knosp, Ines Vergnolle, Clotilde Bravetti, Alban Canali, Amandine Houvert, Laetitia Largeaud, Christian Daveaux, Laila Zaroili, Chloe Friedrich, Ismael Boussaid, Loria Zalmai, Carole Almire, Odile Beyne-Rauzy, Lise Willems, Didier Bouscary, Olivier Gandrillon, Michaela Fontenay, Oliver Kosmider, Francois Vergez, Nicolas Chapuis

    Published in HemaSphere (2023-08-01)
    Get full text
    Article


  4. 4

    Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies by Charikleia Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, Emmanuel Raffoux, Bruno Quesnel, Agnes Guerci, François Dreyfus, Sabine Brechignac, Christian Berthou, Thomas Prebet, Yosr Hicheri, Maya Hacini, Jacques Delaunay, Marie-Pierre Gourin, Jean-Marie Camo, Hacene Zerazhi, Anne-Laure Taksin, Laurence Legros, Bachra Choufi, Pierre Fenaux

    Published in Haematologica (2010-06-01)
    Get full text
    Article


  5. 5

    A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure by Marie Sébert, Aline Renneville, Cécile Bally, Pierre Peterlin, Odile Beyne-Rauzy, Laurence Legros, Marie-Pierre Gourin, Laurence Sanhes, Eric Wattel, Emmanuel Gyan, Sophie Park, Aspasia Stamatoullas, Anne Banos, Kamel Laribi, Simone Jueliger, Luke Bevan, Fatiha Chermat, Rosa Sapena, Olivier Nibourel, Cendrine Chaffaut, Sylvie Chevret, Claude Preudhomme, Lionel Adès, Pierre Fenaux

    Published in Haematologica (2019-08-01)
    Get full text
    Article


  6. 6

    A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents by Sylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, Aline Renneville, Odile Beyne-Rauzy, Thomas Prébet, Sophie Park, Aspasia Stamatoullas, Agnes Guerci-Bresler, Stéphane Cheze, Gérard Tertian, Bachra Choufi, Laurence Legros, Jean Noel Bastié, Jacques Delaunay, Marie Pierre Chaury, Laurence Sanhes, Eric Wattel, Francois Dreyfus, Norbert Vey, Fatiha Chermat, Claude Preudhomme, Pierre Fenaux, Claude Gardin

    Published in Haematologica (2016-08-01)
    Get full text
    Article


  7. 7

    Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia by Vincent Jachiet, Guillaume Moulis, Jérome Hadjadj, Julie Seguier, Kamel Laribi, Nicolas Schleinitz, Norbert Vey, Karim Sacre, Bertrand Godeau, Odile Beyne-Rauzy, Romain Bouvet, Jonathan Broner, Natacha Brun, Thibault Comont, Clément Gaudin, Olivier Lambotte, Lenaïg Le Clech, Pierre Peterlin, Frédérique Roy-Peaud, Clémentine Salvado, Mathilde Versini, Françoise Isnard, Jean Emmanuel Kahn, Delphine Gobert, Lionel Adès, Pierre Fenaux, Olivier Fain, Arsène Mekinian

    Published in Haematologica (2021-02-01)
    Get full text
    Article


  8. 8

    Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes by Louise de Swart, Simon Crouch, Marlijn Hoeks, Alex Smith, Saskia Langemeijer, Pierre Fenaux, Argiris Symeonidis, Jaroslav Cermâk, Eva Hellström-Lindberg, Reinhard Stauder, Guillermo Sanz, Moshe Mittelman, Mette Skov Holm, Luca Malcovati, Krzysztof Mądry, Ulrich Germing, Aurelia Tatic, Aleksandar Savic, Antonio Medina Almeida, Njetocka Gredelj-Simec, Agnes Guerci-Bresler, Odile Beyne-Rauzy, Dominic Culligan, Ioannis Kotsianidis, Raphael Itzykson, Corine van Marrewijk, Nicole Blijlevens, David Bowen, Theo de Witte, on behalf of the EUMDS Registry Participants

    Published in Haematologica (2020-03-01)
    Get full text
    Article


  9. 9

    Long‐term follow‐up and combined Phase 2 results of eprenetapopt and azacitidine in patients with TP53 mutant MDS/AML by David A. Sallman, Rami S. Komrokji, Amy E. Dezern, Marie Sebert, Guillermo Garcia‐Manero, Ramy Rahmé, Eric S. Winer, Jacqueline Lehmann‐Che, Gail J. Roboz, Isabelle Madelaine, Mikkael A. Sekeres, Pierre Peterlin, Onyee Chan, Odile Beyne‐Rauzy, Andrew Kuykendall, Christian Recher, Amy McLemore, Aspasia Stamatoullas, Ling Zhang, Lise Willems, Qianxing Mo, Emmanuel Raffoux, Lisa Nardelli, Céline Berthon, Najla H. Al Ali, Bruno Quesnel, Eric Padron, Hagop M. Kantarjian, Alan F. List, Lionel Ades, Jeffrey E. Lancet, Pierre Fenaux, Thomas Cluzeau

    Published in HemaSphere (2025-07-01)
    Get full text
    Article


Search Tools: